Histogenics Corp.
Histogenics Corp. is listed today as Ocugen, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2020 | $14 M | Private placement after listing | $10 to $50 million | equity, debt | SEC | |
| Sep 2016 | $30 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Dec 2013 | $10 M | No. 1 | $10 to $50 million | equity | SEC | |
| Jul 2012 | $38 M | Issued in a merger or acquisition | $10 to $50 million | equity, options | SEC | |
| May 2011 | $34 M | Issued in a merger or acquisition | $10 to $50 million | equity, debt | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Histogenics Corp. chose not to state its revenue in its newest notice of a funding round (May 2020).
SEC Form D · May 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · May 2020
That is all the official record says: Histogenics Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Histogenics Corp. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Kevin Rakin | Person | not stated | not stated | Held Series A and A-1 preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Sofinnova Management VIII, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Sofinnova Venture Partners VIII, L.P. | Venture capital | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Split Rock Partners II, LP | Fund or asset manager | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Split Rock Partners II Management, LLC | Fund or asset manager | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Wilmslow Estates Ltd | Company | not stated | not stated | Held Series A and A-1 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 17 investors.
Largest shareholders today
Institutions holding Ocugen, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$29 M8.18%
- State Street Corp$20 M5.76%
- Vanguard Capital Management LLC$15 M4.17%
- Millennium Management LLC$13 M3.59%
- UBS Group AG$10 M2.82%
- Geode Capital Management, LLC$9 M2.55%
- RTW Investments, LP$7 M1.96%
- Two Sigma Investments, LP$4 M1.16%
- Ikarian Capital, LLC$4 M1.05%
- GMT Capital Corp$4 M1.03%
- Hennion & Walsh Asset Management, Inc.$3 M1.00%
- Vanguard Portfolio Management LLC$3 M1.00%
- Goldman Sachs Group Inc$3 M0.98%
- Northern Trust Corp$3 M0.81%
- Vanguard Fiduciary Trust Co$2 M0.70%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Daniel B Jorgensen | Executive officer | May 2020 |
| Kelly B Beck | Executive officer | May 2020 |
| Rasappa B Arumugham | Executive officer | May 2020 |
| Sanjay B Subramanian | Executive officer | May 2020 |
| Shankar Musunuri | Chief Executive Officer and Chairman | May 2020 |
| Vijay B Tammara | Executive officer | May 2020 |
| Adam Gridley | Executive officer | Oct 2016 |
| Peter Greenleaf | Executive officer | Jan 2014 |
| Kevin McArdle | Executive officer | Nov 2012 |
| Patrick O'Donnell | Executive officer | Nov 2012 |
| Brian J.B. Callahan | Executive officer | May 2011 |
| Kirk J.B. Andriano | Executive officer | May 2011 |
| Laurence J.B. Tarrant | Executive officer | May 2011 |
| Junge Zhang | Director | May 2020 |
| Kristen B Castillo | Director | May 2020 |
| Manish B Potti | Director | May 2020 |
| Prabhavathi B Fernandes | Director | May 2020 |
| Ramesh Kumar | Director | May 2020 |
| Shankar Musunuri | Chief Executive Officer and Chairman | May 2020 |
| Suha B Taspolatoglu | Director | May 2020 |
| Uday B Kompella | Director | May 2020 |
| Adam Gridley | Director | Oct 2016 |
| David J. Gill | Director | Oct 2016 |
| Garheng Kong, M.D., Ph.D. | Director | Oct 2016 |
| John J. Johnson | Director | Oct 2016 |
| Jonathan J. Lieber | Director | Oct 2016 |
| Joshua Baltzell | Director | Oct 2016 |
| Kevin Rakin | Director | Oct 2016 |
| Michael Lewis | Director | Oct 2016 |
| Garheng Kong, M.D., Ph.D | Director | Jan 2014 |
| John Johnson | Director | Jan 2014 |
| Peter Greenleaf | Director | Jan 2014 |
| Garheng Kong | Director | Nov 2012 |
| Patrick O'Donnell | Director | Nov 2012 |
| Dominic J.B. Redfern | Director | May 2011 |
| Harry J.B. Rein | Director | May 2011 |
| Michael J.B. Lewis | Director | May 2011 |
| Patrick J.B. Fortune | Director | May 2011 |
| Philip J.B. Press | Director | May 2011 |
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.